Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Zanubrutinib Tablet vs Capsule and Food Effect
NCT05547399Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jun 2022
- Primary completion
- Dec 2022
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zanubrutinib in B cell malignancies (2 cohorts), sponsored by BeiGene. Primary endpoints: Area under the plasma concentration-time curve from time 0 extrapolated to infinity, Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration and 5 more. Started Jun 2022; status: completed.
02
Drugs
zanubrutinib
03
Conditions
B cell malignancies
Beyond the preview
Go deeper on NCT05547399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547399.